Einst und Jetzt im Fokus

Zürich (ots) - Der Publikumsrat SRG.D beschäftigte sich in der August-Sitzung einerseits mit «Tama ...

AmVac AG

AmVac AG strengthens management
Ali Pashazadeh appointed CEO effective immediately

Zug (ots) - The Board of Directors of AmVac AG has appointed Ali Pashazadeh with immediate effect as Chief Executive Officer of the Zug based life science company focused on innovative vaccines. After transferring her operating management responsibilities to Ali Pashazadeh, company founder Melinda Karpati will focus on chairing the Scientific Committee of the AmVac Board of Directors. "As over the last years key decisions have been taken and foundations been laid, the transition in AmVac's management is the logical next step in the development of our company", comments Melinda Karpati. The Board of Directors is expressing its gratitude for her achievements in leading AmVac and is looking forward to the continuing collaboration.

Ali Pashazadeh is the founder of Treehill Partners, an execution-focused consultancy and interim management firm led by four seasoned healthcare professionals focused on the hands-on support of international companies in the Biopharma space. Treehill Partners will work alongside management in optimizing operations and aiding the transformation of AmVac into a market-facing entity.

Prior to founding Treehill Partners, Ali Pashazadeh held senior healthcare advisory positions at Blackstone, UBS and Goldman Sachs. He is a trained surgeon, holding an MBBS and BSc from St Mary's Hospital Medical School, London as well as an MBA from London Business School.

Marie Christine Kopkow, chairperson of the Board of Directors of AmVac AG, explains: "Ali Pashazadeh and the Treehill Partners team will enhance AmVac's management with their extensive experience in the international healthcare industry, particularly in pharmaceuticals, medical technology, diagnostics and life sciences. Their industrial network from previous advisory and hands on experience with key industry leaders including Allergan, AstraZeneca, Bayer, GlaxoSmithKline and Novartis will be key to our future success."

AmVac - Tomorrow's Vaccines today

AmVac AG is a biopharmaceutical company developing and marketing innovative vaccines. The life-science company was founded in 2005, is headquartered in Zug, Switzerland and has research laboratories in Germany and Italy, and a manufacturing operation in Hungary. Based on exclusive licenses from leading German scientific institutes of the Helmholtz- and Max-Planck societies and own acquired IP, AmVac has developed an innovative portfolio of seven vaccine candidates and three platform technologies - Lactobacillus, Sendai and Malp. The most advanced product of AmVac is Gynevac, based on the Lactobacillus platform. Previously already approved for selected indications in certain geographies, the product is currently being developed for the treatment of certain highly prevalent urogenital diseases on a broad international level. With its particularly favourable safety profile, Gynevac could, for the first time, offer an effective treatment or prevention of non-malignant prostate enlargement and inflammation, bacterial inflammation and infection with trichomonads, virtually free of side effects. Lastly, AmVac is currently directing a part of its research program to a promising Ebola vaccine in its pipeline. 2I2

Contact:

Marie Christine Kopkow
Chairperson of the Board of Directors
T +41 41 725 32 38
kopkow@amvac.eu



Das könnte Sie auch interessieren: